High quality managers and scientists have left. Others hang around. The replacements will be low cost, likely on working visas staying temporarily. No commitment, just to pickup some information for interviewing elsewhere.
He did not accomplish a lot at Genentevh, other than closing manufacturing facilities.
This may be anticipated at Biomarin as well with letting many people go. He will bring people from Genetech and will get rid of people who were hired from other companies like Merck, Amgen and other. This may also affect operations in Ireland that lack competence. Since improving pipeline cannot be done, he will act quickly by letting people go to improve the bottom line. Would also replace ineffective research team.
Many changes coming soon.